- active not recruitingPHASE2
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This study is testing a new drug, PF-07220060, for people with advanced cancers like breast, prostate, and lung cancer. Researchers want to see if it's safe and how it works, both by itself and with other cancer medicines.
United States · Argentina · China - recruiting
PARTial BREast RECONstruction With Chest Wall Perforator Flap
This study looks at how women fare after breast cancer surgery where part of the breast is removed and rebuilt using a patient's own tissue from the chest wall. It aims to understand the results and experiences of this type of reconstruction.
United Kingdom - recruitingPHASE3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
This study is for people with advanced breast cancer that has a specific genetic change (PIK3CA). It's testing a new drug, Tersolisib, alongside other cancer medicines, to see if it's safe and helps treat the disease effectively.
United States · Argentina · Australia - active not recruitingPHASE2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
This study looks at a new combination of experimental drugs, disitamab vedotin and tucatinib, for advanced breast or stomach cancers that have a specific marker called HER2. It aims to see how safe and effective this treatment is, and what side effects it might cause.
United States · Australia · Canada - authorisedHuman Pharmacology (Phase I)- First administration to humans
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
This study is testing a new medicine called LY4257496 for people with certain types of cancer, including breast, bowel, prostate, and womb cancer, especially if it has spread. It's the first time this medicine is being given to people, to check if it's safe and how it works in the body.
Germany - recruitingPHASE3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
This study is looking into a new drug called Pumitamig for people with a type of breast cancer called triple-negative breast cancer. It compares Pumitamig plus standard chemotherapy with a dummy drug (placebo) plus chemotherapy to see if it's safe and effective.
United States · Australia · Belgium - recruiting
Sensitivity of Organoids to Predict Treatment Outcome in Breast Cancer Metastases
This study aims to grow tiny copies of breast cancer from patients' removed tumours (called organoids). Researchers will test how these organoids react to cancer treatments to see if they can predict how well patients will respond to the same treatments.
United Kingdom - active not recruitingPHASE3
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
This study looks at a new drug, imlunestrant, for early breast cancer. It compares it to standard hormone treatments like tamoxifen, anastrozole, letrozole, and exemestane. The goal is to see if imlunestrant works better for patients whose cancer is at higher risk of returning.
United States · Argentina · Australia - recruitingPHASE3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
This study is for people with advanced HR+/HER2- breast cancer. It compares a new drug, sacituzumab tirumotecan (alone or with pembrolizumab), against standard chemotherapy, to see which treatment best controls the cancer's growth.
United States · Argentina · Australia - active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
This study looks at a new treatment for a type of breast cancer that has come back or spread. It combines a drug called pembrolizumab with standard chemotherapy to see if it works better than chemotherapy alone for HR+/HER2- breast cancer.
United States · Argentina · Australia - recruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
This study looks for better ways to treat early-stage, high-risk breast cancer. It tests a new targeted therapy, sacituzumab tirumotecan, with other standard treatments to see if it reduces cancer and helps people live longer without the cancer returning.
United States · Argentina · Australia - recruitingPHASE3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
This study looks at a new drug, patritumab deruxtecan, for a certain type of advanced breast cancer. It aims to see if this new treatment helps people live longer or stops cancer from growing compared to standard treatments like chemotherapy.
United States · Argentina · Australia - recruitingNA
Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors
This study looks at a new programme, PACHA, to help women with breast cancer stick to their hormone treatment. It checks if the programme, run from local pharmacies, is easy to use, helpful, and could be studied on a bigger scale.
Canada - recruitingNA
Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)
This study looks into a new, faster way to give radiation treatment for early-stage breast cancer. Instead of many sessions, it uses a single, high-dose treatment to see if it's just as good at treating the cancer and has good cosmetic results.
France · Germany · Hungary - recruitingPHASE4
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
This study looks at how well a breast cancer drug called ribociclib works for women with a specific type of advanced breast cancer and why it might or might not work. It also checks for side effects and how patients feel.
Germany - recruiting
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
This study looks at how a new breast cancer treatment, trastuzumab deruxtecan (T-DXd), works in real life for people with advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It will also gather information on how patients feel and their experiences with the treatment.
Germany - recruiting
Establishment of a Tumor Bank for Blood Samples
This study is setting up a collection of blood samples from people with cancer and healthy volunteers. This collection, called a tumour bank, will help scientists understand cancer better and develop new treatments in the future.
Austria · Belgium · Germany - active not recruitingPHASE3
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
This study for advanced ER+, HER2- breast cancer tests a new drug called imlunestrant. Researchers want to see if it works better than standard hormone therapy, and if adding abemaciclib helps even more. It aims to find better treatments for this common type of breast cancer.
United States · Argentina · Australia - active not recruitingPHASE1, PHASE2
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is testing a new drug, BT8009, alone or with another drug called pembrolizumab, for people with advanced cancers. It aims to find a safe and effective dose, understand how the body handles it, and see how well it works against different cancer types.
United States · Canada · France - recruitingPHASE1, PHASE2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
This study looks at new drug combinations (Elacestrant and Abemaciclib) for people with breast cancer that has spread to the brain. It aims to find the right dose and see how well the new combination works for ER-positive, HER-2 negative breast cancer.
United States · Belgium · France - active not recruitingPHASE1
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
This study looks at a new drug, H3B-6545, combined with an existing drug, palbociclib, for women with advanced breast cancer. The main goal is to find a safe dose of this combination for breast cancer that is positive for oestrogen receptors and negative for HER2.
United States · United Kingdom - active not recruiting
Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI
This study aims to find out if special MRI scans can spot early signs of heart strain in women with breast cancer who are having certain treatments. This could help doctors protect their hearts and improve long-term health.
Canada - active not recruitingPHASE3
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
This study looks at new ways to treat advanced breast cancer that is sensitive to hormones and doesn't have too much HER2 protein. It compares a new drug called abemaciclib plus fulvestrant to fulvestrant alone, to see which helps patients live longer without their cancer growing.
United States · Australia · Belgium - not yet recruitingPHASE2
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
This study looks at a new drug, imlunestrant, for premenopausal women with a common type of early breast cancer. Researchers want to see how it affects cancer cells and the ovaries, comparing it to an existing treatment called tamoxifen. It’s for women whose breast cancer is sensitive to hormones.
United States · Belgium · France - recruitingPHASE2, PHASE3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
This study is testing a new drug, iza-bren, for advanced triple-negative breast cancer or ER-low, HER2-negative breast cancer. It compares iza-bren with standard chemotherapy in patients who haven't had previous treatment for advanced disease and can't receive certain immunotherapy drugs.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
This study looks into a new medicine, patritumab deruxtecan, for HER2-positive breast cancer that has spread and can't be removed by surgery. Researchers want to see if it's safe, how well people tolerate it, and if it can shrink or get rid of the cancer.
United States · Canada · Israel